CORBUS PHARMACEUTICALS HOLDI (CRBP)

Notable Monday Option Activity: CRBP, ATSG, NBR

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight...

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that...

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and...

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit

NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that...

Corbus Pharmaceuticals Holdings is Now Oversold (CRBP)

Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects

Shares of Corbus, which is working on a similar drug, also crashed on Novo Nordisk's news.

Noteworthy Wednesday Option Activity: PAG, CRBP, NNOX

Notable Monday Option Activity: RSI, RIOT, CRBP